Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)
- PMID: 10880752
- DOI: 10.1016/s0301-472x(00)00155-7
Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)
Abstract
A hierarchy of progenitor cells is thought to exist in human acute myeloid leukemia (AML), with only the most primitive cells capable of proliferating to maintain the malignant clone. To further characterize this AML cell hierarchy, we evaluated the coexpression of CD34 and c-kit (CD117) on cells that are capable of long-term proliferation in vitro and in vivo.AML cells were sorted for coexpression of CD34 and c-kit (CD117) using two c-kit monoclonal antibodies (mAbs), clones 95C3 and 104D2. Sorted subfractions were evaluated for the ability to produce colony-forming units (CFU) for up to 8 weeks in suspension culture (SC) and for the capacity to repopulate NOD/SCID mice. When expression of c-kit on blood cells from 19 AML patients at diagnosis was compared using both mAbs, expression defined by 104D2 (34% +/- 6% c-kit(+)) was somewhat higher than that defined using 95C3 (18% +/- 4%). AML cells were sorted for coexpression of CD34 and c-kit using both c-kit mAbs, and the subfractions were assayed in vitro and in vivo. Whereas the majority of AML blast cells lacked expression of CD34, most AML cells capable of proliferating to produce CFU after 4 to 8 weeks in SC were CD34(+)/c-kit(-). Cultures of sorted CD34(+)/c-kit(-) cells, supplemented with steel factor, were composed of a large proportion (18% to 87%) of CD34(+)/c-kit(+) cells after 1 week, suggesting that either c-kit expression was upregulated or CD34(+)/c-kit(+) cells were produced. Moreover, the CD34(+)/c-kit(-) subfraction was found to be capable of responding to steel factor alone to produce CFU after 4 weeks in SC. In most AML patients tested (11/15), the only sorted subfraction capable of engrafting NOD/SCID mice was CD34(+)/c-kit(-). The CD34(+)/c-kit(+) subfraction from only 2 of the 15 patients and CD34(-) cells from 3 patients also engrafted the NOD/SCIDs. Only the CD34(+)/c-kit(+) subfraction of normal bone marrow engrafted. These studies suggest that primitive AML cells capable of long-term proliferation in vitro and NOD/SCID repopulation differ from primitive normal progenitor cells in their lack of surface expression of c-kit.
Similar articles
-
Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-.Blood. 1998 Dec 1;92(11):4325-35. Blood. 1998. PMID: 9834239
-
CD133 (AC133) expression on AML cells and progenitors.Cytotherapy. 2001;3(6):449-59. doi: 10.1080/146532401317248054. Cytotherapy. 2001. PMID: 11953029
-
Characterization of a hierarchy in human acute myeloid leukemia progenitor cells.Blood. 1996 Jun 1;87(11):4754-61. Blood. 1996. PMID: 8639846
-
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression.Leuk Lymphoma. 1997 Jan;24(3-4):221-8. doi: 10.3109/10428199709039010. Leuk Lymphoma. 1997. PMID: 9156652 Review.
-
Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.Acta Haematol. 1996;95(3-4):257-62. doi: 10.1159/000203893. Acta Haematol. 1996. PMID: 8677752 Review.
Cited by
-
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.Nat Rev Drug Discov. 2009 Oct;8(10):806-23. doi: 10.1038/nrd2137. Nat Rev Drug Discov. 2009. PMID: 19794444 Review.
-
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors.EMBO J. 2012 Sep 12;31(18):3704-17. doi: 10.1038/emboj.2012.227. Epub 2012 Aug 17. EMBO J. 2012. PMID: 22903061 Free PMC article.
-
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.Cancers (Basel). 2021 May 26;13(11):2597. doi: 10.3390/cancers13112597. Cancers (Basel). 2021. PMID: 34073205 Free PMC article.
-
Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy.Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.25. doi: 10.1002/0471141755.ph1425s61. Curr Protoc Pharmacol. 2013. PMID: 23744710 Free PMC article. Review.
-
Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.Blood. 2005 Jul 1;106(1):254-64. doi: 10.1182/blood-2004-12-4664. Epub 2005 Mar 8. Blood. 2005. PMID: 15755900 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous